Analysts Set uniQure (NASDAQ:QURE) PT at $38.89

Shares of uniQure (NASDAQ:QURE) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $38.89.

Several analysts recently commented on QURE shares. Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Guggenheim restated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a report on Tuesday, March 11th.

uniQure Trading Down 3.8 %

Shares of QURE stock opened at $13.13 on Tuesday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The stock has a market capitalization of $710.03 million, a P/E ratio of -2.65 and a beta of 0.36. The firm’s 50 day moving average is $13.80 and its 200 day moving average is $10.70.

Insider Transactions at uniQure

In related news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 over the last three months. Corporate insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC purchased a new stake in uniQure in the 4th quarter worth $38,410,000. Franklin Resources Inc. purchased a new stake in shares of uniQure in the third quarter worth about $7,360,000. RTW Investments LP lifted its position in shares of uniQure by 8,936.3% in the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after buying an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after buying an additional 794,459 shares in the last quarter. Finally, Boxer Capital Management LLC bought a new stake in uniQure in the 4th quarter worth approximately $13,245,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.